The diversity of drimane hydroquinones was significantly expanded by the facile construction of (+)-chromazonarol relevant natural products, isomers, and analogues for the discovery of new pharmaceutical leads. The structure-activity relationship of (+)-chromazonarol relevant (non)-natural products was delineated via the synergistic interaction of the programmable synthesis and bioactivity-guided screening. The first divergent derivatization of (+)-chromazonarol demonstrated that the phenolic hydroxyl group is one inviolable requirement for antifungal effect. Pinpoint modification of (+)-yahazunol manifested the position of hydroxyl group was crucial for both antifungal and antitumor activities. (+)-Albaconol, (+)-neoalbaconol, and two (+)-yahazunol isomers (24 and 25) proved to be the novel pharmaceutical leads. The probable macromolecular targets were estimated to deliver new information about the biological potentials resident in (+)-yahazunol relevant products. This work also featured the first synthesis of (+)-albaconol and (+)-neoalbaconol, the first biological exploration of (+)-dictyvaric acid and improved preparation of (+)-8-epi-puupehedione and a promising pelorol analogue.

drimane 对苯二酚的多样性通过 (+)-chromazonarol 相关天然产物、异构体和类似物的简便构建显着扩大，以发现新的药物先导物。(+)-chromazonarol 相关（非）天然产物的构效关系通过可编程合成和生物活性引导筛选的协同作用进行描述。(+)-chromazonarol 的第一次不同衍生表明酚羟基是抗真菌作用不可侵犯的要求。(+)-yahazunol 的精确修饰表明羟基的位置对于抗真菌和抗肿瘤活性都至关重要。(+)-Albaconol、(+)-neoalbaconol 和两种 (+)-yahazunol 异构体 ( 24和25) 被证明是新的药物先导。估计可能的大分子靶标可提供有关 (+)-yahazunol 相关产品中存在的生物潜力的新信息。该工作还首次合成了 (+)-albaconol 和 (+)-neoalbaconol，首次对 (+)-dictyvaric acid 进行了生物学探索，并改进了 (+)-8- epi -puupehedione 和有前途的 pelorol 类似物的制备。